From: Paul Finnegan
Sent: Wednesda , Se. em er , :
To:
Cc: Jeffrey Port
Subject: Angiocrine Bioscience "numbers". requested
Attachments: Angiocrine - Capitalization Table (2015.7.10) Summary v150901.pdt Angiocrine Comp
Analysis Trout Capital ... Angiocrine_v150818 0634 PFCGD FINAL.xlsx; Angiocrine
Bioscience Inc 3.25 year Forecast_$5M+$25M v150902 0625.xlsx
Dear Jeffrey,
Attached are the 3 deliverables you requested when w= met you at your ... style="font-size:9.0ptfont-family:"Arial",sans-seritcolo=1222222">
Chief Executive Officer
Angiocrine Bioscience, Inc.4=pan>
3570 Carmel Mountain Rd, Suite 200,=/o:p>
San Diego, CA 92130
Angiocrine
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02397672.pdf
EFTA00327843Set 9
2016-03-153p700w
Paul Finnegan c:a
To: "jeevacation®gmail.com" <jeevacation®gmail.com>
Cc: Jeffrey Port <
Subject: RE: Angiocrine Bioscience Update
Date: Tue, 15 Mar 2016 01:09:07 +0000
Dear Jeffrey,
Since ... series of advances which we are
excited to share with you.
Just to refresh, Angiocrine Bioscience has developed technologies and therapeutic candidates designed to initiate
regeneration of tissue and organ ... also eligible for
further CIRM funding for clinical trials studying E-CEL UVEC.
Angiocrine technologies have now been awarded 4 out of 4 highly competitive grants: (1) CIRM, (2) SBIR
https://www.justice.gov/epstein/files/DataSet%209/EFTA00327843.pdf
EFTA01046722Set 9
2017-05-082p685w
From: Boris Nikolic
To: Jeffrey E.
Subject: Re: Intro via Dr Jeff Port - Angiocrine Bioscience Update
Date: Mon, 08 May 2017 06:02:41 +0000
Thank you.
Would not come ... Boris Nikolic
Subject: Fwd: Intro via Dr Jeff Port - Angiocrine Bioscience Update
thoughts
Forwarded message
From: Paul Finnegan <
Date: Sun, May 7, 2017 at 4:03 PM
Subject: RE: Intro ... Jeff Port - Angiocrine Bioscience Update
To: "jeevacation@gmail.com" <jeevacation@gmail.com>
Cc: Jeffrey Port < >, IT
Dear Jeffrey,
Hope this email finds all is well with you and your family. It's been about
https://www.justice.gov/epstein/files/DataSet%209/EFTA01046722.pdf
EFTA00292514Set 9
2017-04-276p1,776w
MEMORANDUM OF TERMS
FOR PRIVATE PLACEMENT OF
SERIES A-1 PREFERRED STOCK OF
ANGIOCRINE BIOSCIENCE, INC.
April 27, 2017
This memorandum summarizes the principal terms of the Series ... Preferred Stock financing of
Angiocrine Bioscience, Inc. (the "Company"). The completion of the transactions contemplated by this
memorandum will be subject to, among other things, satisfactory completion of financial
https://www.justice.gov/epstein/files/DataSet%209/EFTA00292514.pdf
EFTA00854723Set 9
2015-06-101p117w
From: Jeffrey Port
To: jeffrey Epstein <jeevacation@gmail.com>
Subject: Fwd: Angiocrine Non-Confidential Deck for Mr. Jeff Epstein
Date: Wed, 10 Jun 2015 14:36:44 +0000
Attachments: Angiocrine_Bioscience_Non-Confidential_Presentationjun_2015_v150608.pptx
Jeff, here ... June 10, 2015 at 9:32:43 AM EDT
To: Jeffrey L Port
Subject: Angiocrine Non-Confidential Deck for Mr. Jeff Epstein
Dear Jeff,
Jun 2015 non-confidential deck attached
https://www.justice.gov/epstein/files/DataSet%209/EFTA00854723.pdf
EFTA02499974Set 11
2015-06-102p223w
jeevacation@gmail.com>
Sent: Wednesday, June 10, 2015 2:55 PM
To: Jeffrey Port
Subject: Re: Angiocrine Non-Confidential Deck for Mr. Jeff Epstein
in the future only numbrs ... Date: June 10, 2=15 at 9:32:43 AM EDT
To: J
Subjec=: Angiocrine Non-Confidential Deck for Mr. Jeff Epstein
=/div>
<=iv dir="ltr">Dear Jeff
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02499974.pdf